An interventional study of Time-Restricted Eating in Metabolic Syndrome, Overweight or Obesity and PreDiabetes, sponsored by Nicolaus Copernicus University. Completed at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Nicolaus Copernicus University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Metabolic Syndrome with a site in Poland — 10 open to participants now, 13 under way, 1 of them phase 3. Metabolic Syndrome · Poland.
Among the 31 studies in Metabolic Syndrome with a site in Poland, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2019, is one of 14 with no phase, and was the 10th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →10 of the 31 studies in Metabolic Syndrome with a site in Poland are open now. Recruiting first, the newest first:
University of Applied Sciences in Nowy Targ · Sites in Poland
Ages 18–35 · Women only · Healthy volunteers
Poznan University of Medical Sciences · Sites in Poland
Ages 15–44
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 96 across the 19 interventional studies, 143 across the 12 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
Nicolaus Copernicus University is the lead sponsor of 19 studies on the registry; 4 are open to participants now.
Nicolaus Copernicus University has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Metabolic Syndrome with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634591Medical University of BialystokThe Bialystok Bariatric Surgery Study | 2026-12-31 |
| NCT07917364University of Applied Sciences in Nowy TargAsprosin and miRNA Expression in Young Women With Metabolic Syndrome | 2027-03 |
| NCT07358533Pomeranian Medical University SzczecinMetabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud | 2027-05 |
| NCT07793487Warsaw University of Life SciencesApplications of a Functional Dairy Product in Diet Therapy | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Metabolic Syndrome with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the clinical trial is to determine the health impact of a dietary intervention known as time-restricted eating (TRE) in patients with metabolic syndrome (defined as the presence of elevated fasting plasma glucose and two or more of the following criteria: increased waist circumference, elevated fasting plasma triglycerides, reduced high-density lipoprotein-cholesterol, elevated blood pressure) and self-reported dietary intake of ≥14 hours per day. Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (myCircadianClock (mCC) app). Glucose homeostasis (blood glucose levels will be monitored continuously for 2 weeks at the baseline, at the end of the monitored intervention, and at the end of the self-directed intervention using a continuous glucose monitor), and other metabolic, neuroendocrine, inflammatory and oxidative stress/antioxidant defense biomarkers, body weight and composition, blood pressure, heart rate, sleep and activity (using mCC app), personal sense of wellness and dietary timing (using health questionnaires) will be evaluated at the baseline, at the end of the monitored intervention, and at the end of the self-directed intervention.
Metabolic syndrome occurs in approximately 30% of adults and is associated with increased risk of cardiovascular disease and type 2 diabetes. Circadian rhythm disruption due to lifestyle including erratic eating patterns may lead to metabolic and neuroendocrine dysfunction, inflammation, oxidative stress, and cardiometabolic diseases. Maintaining a daily rhythm of eating and fasting cycles sustains a robust circadian rhythm which improves cellular bioenergetics and metabolism. Recent studies support the notion that restricting a period of food intake to 8-12 hours a day (time-restricted eating, TRE) can prevent and reverse obesity and metabolic dysfunction.
The main purpose of the clinical trial is to determine the health impact of TRE in patients with metabolic syndrome (defined as the presence of elevated fasting plasma glucose and two or more of the following criteria: increased waist circumference, elevated fasting plasma triglycerides, reduced high-density lipoprotein-cholesterol, elevated blood pressure) and self-reported dietary intake of ≥14 hours per day. Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (myCircadianClock (mCC) app, developed by the Salk Institute for Biological Studies). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician. Glucose homeostasis (blood glucose levels will be monitored continuously for 2 weeks at the baseline, at the end of the monitored intervention, and at the end of the self-directed intervention using a continuous glucose monitor), and other metabolic, neuroendocrine, inflammatory and oxidative stress/antioxidant defense biomarkers, body weight and composition, blood pressure, heart rate, sleep and activity (using mCC app), personal sense of wellness and dietary timing (using health questionnaires) will be evaluated at the baseline, at the end of the monitored intervention, and at the end of the self-directed intervention. The investigators will assess for compliance with TRE using mCC app.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Metabolic syndrome, defined as the presence of elevated fasting plasma glucose ≥ 100 mg/dL and two or more of the following criteria:
Elevated waist circumference: ≥ 102 cm in men, ≥ 88 cm in women; Fasting plasma triglycerides ≥ 150 mg/dL (or on drug treatment for elevated triglycerides); Reduced High-density lipoprotein (HDL)-cholesterol \< 40 mg/dL in men, \< 50 mg/dL in women (or drug treatment for reduced HDL-cholesterol); Elevated blood pressure, Systolic blood pressure ≥ 130 mm Hg and/or diastolic blood pressure ≥ 85 mm Hg (or drug treatment for hypertension).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Time-Restricted Eating
Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
Change in body weight
Body weight (kg) as measured in fasted state on a digital scale
Time frame: Baseline and after 14 weeks
Change in fasting glucose concentration
Fasting plasma glucose concentration (mg/dl)
Time frame: Baseline and after 14 weeks
Body weight
Body weight (kg) as measured in fasted state on a digital scale
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Body mass index
Body mass index (kg/m\^2) as calculated from body weight (kg) and height (m)
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Mean glucose
Glucose levels as measured by continuous glucose monitor (mg/dl) for 14 days at baseline, after 14 weeks, and after 26 weeks
Time frame: Changes from baseline. Measured at baseline, after 14 weeks, and after 26 weeks
Fasting glucose
Fasting glucose levels as measured by continuous glucose monitor (mg/dl) for 14 days at baseline, after 14 weeks, and after 26 weeks
Time frame: Changes from baseline. Measured at baseline, after 14 weeks, and after 26 weeks
Lipids
Fasting blood concentrations of lipids: total cholesterol (mg/dl), LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), and triglycerides (mg/dl)
Time frame: Changes from baseline. Measured in the blood in the fasted state at baseline, after 14 weeks, and after 26 weeks
Fat mass
Fat mass percentage (%) as measured by body composition analyzer (using bioelectric impendence technology)
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
HbA1c
HbA1c (%) assessed from blood samples
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Metabolic and neuroendocrine biomarkers
Fasting blood concentrations of metabolic and neuroendocrine biomarkers including but not limited to: free fatty acids, insulin, insulin-like growth factor-1, resistin, adiponectin, leptin, visfatin, irisin, ghrelin, omentin-1, and melatonin
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Inflammatory biomarkers
Fasting blood concentrations of inflammatory biomarkers including but not limited to: high sensitivity C-reactive protein, interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-α, tumor growth factor-β1, growth/differentiation factor 15
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Oxidative stress/antioxidant defense biomarkers
Fasting blood concentrations of oxidative stress/antioxidant defense biomarkers including but not limited to: superoxide dismutase-1, catalase, glutathione peroxidase, oxidized LDL, thiobarbituric acid reactive substances, conjugated dienes, malondialdehyde, 4-hydroxynonenal, vitamin A, and vitamin E
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Waist circumference
Waist circumference (cm) as measured using tape measure
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Blood pressure
Systolic and diastolic blood pressure (mmHg) measured under resting and fasting conditions
Time frame: Changes from baseline. Fasted state at baseline, after 14 weeks, and after 26 weeks
Heart rate
Heart rate (bpm) measured under resting conditions during measurements of blood pressure
Time frame: Changes from baseline. Measured at baseline, after 14 weeks, and after 26 weeks
Energy intake
Energy intake (kcal/day) assessed from diet records
Time frame: Registered at baseline, after 14 weeks, and after 26 weeks
Timing of dietary intake
Timing of dietary intake (hh:mm) assessed from diet records and from the chrono-nutrition questionnaire
Time frame: Changes from baseline. Registered at baseline, after 14 weeks, and after 26 weeks
Self-reported sleepiness
Self-reported sleepiness as assessed from the questionnaire the Epworth Sleepiness Scale
Time frame: Changes from baseline. Assessed at baseline, after 14 weeks, and after 26 weeks
Self-reported sleep quality
Self-reported sleep quality as assessed from the questionnaire Pittsburgh Sleep Quality Index
Time frame: Changes from baseline. Assessed at baseline, after 14 weeks, and after 26 weeks
Self-reported chronotype
Self-reported chronotype as assessed from the Munich Chronotype Questionnaire
Time frame: Changes from baseline. Assessed at baseline, after 14 weeks, and after 26 weeks
Self-reported overall health and wellbeing
Self-reported overall health and wellbeing as assessed from the questionnaire Self-reported health (SF-36 health survey)
Time frame: Changes from baseline. Assessed at baseline, after 14 weeks, and after 26 weeks
Duration of eating period
Duration from the first to last caloric intake over 24-hour cycle, collected via the smartphone app (mCC app)
Time frame: Changes from baseline. Assessed at baseline, after 14 weeks, and after 26 weeks
Plan to share: No
Ran from Oct 2019 to primary completion in Sep 2023, 46 months.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 46 months is above that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Apr 2024 → Sep 2023 and completion Dec 2024 → Dec 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nicolaus Copernicus University